Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / EFEMP1

EFEMP1

Basics

Aliases:
This biomarker is also known as:
  • Extracellular protein S1-5,
  • S1-5,
  • Fibulin-3,
  • FBLN3,
  • fibulin 3,
  • MTLV,
  • EGF containing fibulin-like extracellular matrix protein 1,
  • FBNL,
  • Fibrillin-like protein,
  • DHRD,

View in BioMuta

Description…

EFEMP1, also known as fibulin-3, binds EGFR, the EGF receptor, inducing EGFR autophosphorylation and the activation of downstream signaling pathways. It may play a role in cell adhesion and migration, and may function as a negative regulator of chondrocyte differentiation. In the olfactory epithelium, it may regulate glial cell migration, differentiation and the ability of glial cells to support neuronal neurite outgrowth. EFEMP1 is up-regulated in malignant gliomas and may play a role in the agressive nature of these tumors by increasing glioma cell adhesiveness and invasive properties.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: EFEMP1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: One
QA State: Under Review

Overview

Inactivation of EFEMP1 due to DNA hypermethylation has been seen in lung, prostate, colorectal, breast, nasopharyngeal, and hepatocellular cancers. EFEMP1 has been shown to be up-regulated in pancreatic adenocarcinoma metastases and possibly glioblastomas.

Performance Comment

EFEMP1 (fibulin-3) levels may be helpful in the diagnosis and prognosis of pleural mesothelioma. Plasma fibulin-3 levels have been shown to differentiate healthy persons with exposure to asbestos from patients with mesothelioma. In conjunction with effusion fibulin-3 levels, plasma fibulin-3 levels can further differentiate mesothelioma effusions from other malignant and benign effusions.

Ovary

Attributes

Phase: One
QA State: Under Review

Overview

A single study of differences in gene expression between ovarian or primary peritoneal serous carcinomas and diffuse malignant peritoneal mesothelioma showed that EFEMP1 was overexpressed in all the mesotheliomas but in none of the ovarian or serous carcinomas.

Performance Comment

No additional ovarian data available.

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.